Latest Observability News

Page 6 of 165
Koonenberry Gold has moved three NSW exploration fronts into the next phase, with Dunedoo drilling complete, Wilga Flats drilling underway and Newmont-funded Junee results pending. The company ended September with A$4.35 million in cash and reported about three quarters of funding at its current expenditure rate.
Maxwell Dee
Maxwell Dee
29 Oct 2026
eMetals has confirmed three scheelite-bearing skarn horizons in the first five holes of its maiden Utah tungsten drilling program, with assays still pending. The explorer also expanded its Mineral Range ground position to 145 claims while ending the quarter with A$1.541 million in cash.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Solis Minerals has completed 2,926 metres of drilling across three projects in Brazil and Peru, with assay results still pending. The explorer is moving into a 5,000-metre Cucho copper programme while holding A$3.97 million in cash, equivalent to about 2.12 quarters of funding at the latest reported operating outflow.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Terramin has fully subscribed its $28.65 million entitlement offer, giving the company funding to pursue development of its flagship Tala Hamza zinc project after ending September with only $188,000 in cash. Site works, tenders and financing discussions are advancing in Algeria, while a copper recovery trial in South Australia has delivered a sharp increase in dissolved copper.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Black Rock Mining has extended the financial close deadline for its US$204 million Mahenge debt facilities to 30 November, but the Tanzanian graphite project remains dependent on new equity. The company held A$2.1 million in cash at quarter end, equivalent to 0.75 quarters of estimated funding.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Chilwa Minerals finished the September quarter with only A$5,000 in cash, but its completed Nasdaq IPO has since delivered about A$4.5 million net and reopened the funding runway. The company is now pressing ahead with Mpyupyu West and Nakombe drilling, although the key exploration results remain outstanding.
Maxwell Dee
Maxwell Dee
29 Oct 2026
BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.
Victor Sage
Victor Sage
29 Oct 2026
American Uranium has increased its Lo Herma uranium resource by 16% and lifted the Indicated portion by 72%, while positive aquifer testing supports the technical case for in-situ recovery. The gains come with a pressing funding question, as AMU reported only 0.4 quarters of available cash at September end.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Po Valley Energy delivered record September-quarter revenue and €2.52 million of net production cash flow, despite moderating Podere Maiar-1 output to manage rising formation water. The ASX-listed gas producer is also moving its next Italian drilling programme through environmental approvals while weighing how to fund development without dilution.
Victor Sage
Victor Sage
29 Oct 2026
Great Boulder Resources has completed more than 57,000 metres of drilling across Peak Hill and Side Well during the September quarter, with high-grade results supporting potential resource growth. The ASX-listed explorer ended the period with A$12.3 million in cash and no debt as it works towards a Peak Hill resource update by year-end.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Vantage Metals has intersected the key geological contact targeted by its maiden Botswana drilling campaign, with trace copper sulphides observed and assays pending. The exploration progress comes alongside A$723,000 in quarter-end cash, equivalent to just 0.3 quarters of estimated funding at the reported outflow rate.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.
Ada Torres
Ada Torres
29 Oct 2026

Browse the archive

Full archive